Standard Biotools (LAB) Net Cash Flow (2010 - 2026)

Standard Biotools (LAB) has 17 years of Net Cash Flow data on file, last reported at $144.5 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $144.5 million, up 1019.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $113.8 million (up 184.63% YoY), and the FY2025 annual result was -$46.4 million, down 139.59% from the prior year.
• Net Cash Flow rose to $144.5 million in Q1 2026 per LAB's latest filing, from -$8.6 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $235.9 million in Q1 2024 and troughed at -$62.5 million in Q3 2023.
• A 5-year average of $14.0 million and a median of -$8.6 million in 2025 frame the typical range for Net Cash Flow.
• On a YoY basis, Net Cash Flow climbed as much as 1885.84% in 2023 and fell as far as 350.3% in 2023.
• A 5-year view of Net Cash Flow shows it stood at $20.8 million in 2022, then tumbled by 235.52% to -$28.2 million in 2023, then slumped by 52.06% to -$42.9 million in 2024, then jumped by 79.91% to -$8.6 million in 2025, then surged by 1777.74% to $144.5 million in 2026.
• Business Quant data shows LAB's Net Cash Flow at $144.5 million in Q1 2026, -$8.6 million in Q4 2025, and -$29.0 million in Q3 2025.